Arcus Biosciences Inc. (NYSE:RCUS) traded today at a new 52-week high of $42.07. Approximately 101,000 shares have changed hands today, as compared to an average 30-day volume of 503,000 shares.
Over the past year, Arcus Biosciences Inc. has traded in a range of $9.85 to $42.07 and is now at $41.02, 316% above that low.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company which focuses on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. The company focuses on an ATP-adenosine pathway which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. The pipeline products of the company include dual and selective A2R antagonists, small-molecule and antibody programs which target solid tumors. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Arcus Biosciences Inc. (NYSE:RCUS) has potential upside of 0.2% based on a current price of $41.02 and analysts’ consensus price target of $41.11.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer